Plasma H3Cit-DNA Discriminates Between Cancer and Inflammation in a Cohort of Patients with Unspecific Cancer Symptoms.

Autor: Wannberg F; Department of Clinical Sciences, Division of Internal Medicine, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden., Hjalmar V; Department of Clinical Sciences, Division of Internal Medicine, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.; Division of Specialist Medical Care, Danderyd Hospital, Diagnostic Center, Stockholm, Sweden., Ng H; Department of Clinical Sciences, Division of Internal Medicine, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.; Department of Medical Cell Biology, SciLifeLab, Uppsala University, Uppsala, Sweden., Johansson C; Division of Specialist Medical Care, Danderyd Hospital, Diagnostic Center, Stockholm, Sweden., Probert F; Department of Chemistry, University of Oxford, Oxford, UK., Phillipson M; Department of Medical Cell Biology, SciLifeLab, Uppsala University, Uppsala, Sweden., Åberg M; Department of Medical Sciences, Clinical Chemistry and SciLifeLab Affinity Proteomics, Uppsala University, Uppsala, Sweden., Gordon M; Division of Internal Medicine, Department of Clinical Sciences, Division of Orthopedics, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden., Mackman N; Division of Hematology, Department of Medicine, UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Rosell A; Department of Clinical Sciences, Division of Internal Medicine, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden., Thålin C; Department of Clinical Sciences, Division of Internal Medicine, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. charlotte.thalin@ki.se.

Publikováno v: Inflammation [Inflammation] 2024 Jun 28. Date of Electronic Publication: 2024 Jun 28.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PO-110 Identification of novel biomarkers to aid in the detection of occult cancer in high-risk patient populations: the BIT and MEDECA studies

Autor: Thålin, C., Rosell, A., Gabrielsson, L., Månsson, M., Aguilera, K., Lundström, S., Söderberg, M., Hjalmar, V., Wallén, H.

Publikováno v: In Thrombosis Research April 2021 200 Supplement 1:S79-S80

Routine imaging for diffuse large B-cell lymphoma in first remission is not associated with better survival:A danish-Swedish population-based study

Autor: El-Galaly, T. C., Jakobsen, L. H., Hutchings, M., De Nully Brown, P., Nilsson-Ehle, H., Szekely, E., Hjalmar, V., Juul Mylam, Karen, Johnsen, H. E., Bøgsted, M., Jerkeman, M.

Publikováno v: El-Galaly, T C, Jakobsen, L H, Hutchings, M, De Nully Brown, P, Nilsson-Ehle, H, Szekely, E, Hjalmar, V, Juul Mylam, K, Johnsen, H E, Bøgsted, M & Jerkeman, M 2015, ' Routine imaging for diffuse large B-cell lymphoma in first remission is not associated with better survival : A danish-Swedish population-based study ', Hematological Oncology
, vol. 33, no. S1, 086, pp. 146 . https://doi.org/10.1002/hon.2227

Background: Routine surveillance imaging plays a limited role in detecting recurrent diffuse large B-cell lymphoma (DLBCL), and the value of routine imaging is controversial. The present population-based study compares the post-remission survival of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::ee28856ad9d74aedad891a9072c3c2ea
https://portal.findresearcher.sdu.dk/da/publications/a359ac9a-bfeb-4120-8ee7-82311ce7ed32

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL)

Autor: Lundin, J, Kimby, E, Bjorkholm, M, Celsing, F, Hale, G, Hjalmar, V, Merup, M, Petrescu, A, Tullgren, O, Waldmann, H, Mellstedt, H, Osterborg, A

Publikováno v: BLOOD. 98(11)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::607a193b06a48d4e43cd51f488cc2516
http://ora.ox.ac.uk/objects/uuid:9cabf927-2488-4a5a-b18a-b4c10106a696